An investigation on behalf of investors, who currently hold shares of Cascadian Therapeutics Inc (USA) (NASDAQ:CASC), was announced concerning whether the takeover of Cascadian Therapeutics Inc by Seattle Genetics, Inc for $10.00 per share is unfair to NASDAQ:CASC stockholders.

The investigation by a law firm concerns whether certain officers and directors of Cascadian Therapeutics Inc breached their fiduciary duties owed to NASDAQ:CASC investors in connection with the proposed acquisition.

Seattle, WA based Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. On January 31, 2018, Seattle Genetics, Inc. (Nasdaq:SGEN) and Cascadian Therapeutics, Inc.(Nasdaq:CASC) announced the signing of a merger agreement under which Seattle Genetics has agreed to acquire Cascadian Therapeutics. Under the terms of the agreement, Seattle Genetics will pay $10.00 per share in cash, or approximately $614 million.

However, the investigation concerns whether the offer is unfair to NASDAQ:CASC stockholders. More specifically, the investigation concerns whether the Cascadian Therapeutics Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.